• 1
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498504.
  • 2
    American Cancer Society. Estimated New Cancer Cases and Deaths by Sex for all Sites. American Cancer Society, United States, 2000 (Table). Accessed March 13 2001.
  • 3
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 831.
  • 4
    Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362: 30515.
  • 5
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 527.
  • 6
    Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 3241.
  • 7
    Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13: 8516.
  • 8
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 13115.
  • 9
    The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993; 341: 135962.
  • 10
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 116979.
  • 11
    Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 23739.
    Direct Link:
  • 12
    Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 34753.
  • 13
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 7849.
  • 14
    Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 78491.
  • 15
    Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 2528.
  • 16
    Graham DY, Go MF. Helicobacter pylori: current status. Gastroenterology 1993; 105: 27982.
  • 17
    Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: S3743.
  • 18
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 3149.
  • 19
    Yoshimura T, Shimoyama T, Fukuda S, Tanaka M, Axon AT, Munakata A. Most gastric cancer occurs on the distal side of the endoscopic atrophic border. Scand J Gastroenterol 1999; 34: 107781.
  • 20
    Sepulveda AR. Molecular testing of Helicobacter pylori-associated chronic gastritis and premalignant gastric lesions: clinical implications. J Clin Gastroenterol 2001; 32: 37782.
  • 21
    Moss SF. Cellular markers in the gastric precancerous process. Aliment Pharmacol Ther 1998; 12: 91109.
  • 22
    Li CQ, Pignatelli B, Ohshima H. Increased oxidative and nitrative stress in human stomach associated with cagA+ Helicobacter pylori infection and inflammation. Dig Dis Sci 2001; 46: 83644.
  • 23
    Davies GR, Simmonds NJ, Stevens TR, et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994; 35: 17985.
  • 24
    Kuipers EJ, Meuwissen SG. Helicobacter pylori and gastric carcinogenesis. Scand J Gastroenterol 1996; 218: 1035.
  • 25
    Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut 1998; 42: 3516.
  • 26
    Peek RM Jr, Moss SF, Tham KT, et al. Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis. J Natl Cancer Inst 1997; 89: 8638.
  • 27
    Rokkas T, Ladas S, Liatsos C, et al. Relationship of Helicobacter pylori CagA status to gastric cell proliferation and apoptosis. Dig Dis Sci 1999; 44: 48793.
  • 28
    Scotiniotis IA, Rokkas T, Furth EE, Rigas B, Shiff SJ. Altered gastric epithelial cell kinetics in Helicobacter pylori-associated intestinal metaplasia: implications for gastric carcinogenesis. Int J Cancer 2000; 85: 192200.
  • 29
    Yang YL, Xu B, Song YG, Zhang WD. Overexpression of c-fos in Helicobacter pylori-induced gastric precancerosis of Mongolian gerbil. World J Gastroenterol 2003; 9: 5214.
  • 30
    Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270: G393400.
  • 31
    Chan FK, To KF, Ng YP, et al. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol Ther 2001; 15: 18793.
  • 32
    Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 7829.
  • 33
    Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 72935.
  • 34
    Wambura C, Aoyama N, Shirasaka D, et al. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 2002; 7: 12938.
  • 35
    Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of Helicobacter pylori-related gastric carcinogenesis. J Pathol 2004; 202: 30512.
  • 36
    Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1: 3150.
  • 37
    Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 2001; 6: 2949.
  • 38
    Cheli R, Giacosa A, Pirasso A. Chronic gastritis: a dynamic process toward cancer. In: Ming, SC, ed. Precursor of Gastric Cancer. New York: Praeger Scientific, 1984: 11729.
  • 39
    Borchard F. Precancerous conditions and lesions of stomach. In: Rugge, M, Arslan-Pagnini, C, Di Mario, F, eds. Carcinoma gastrico e lesioni precancerose dello stomaco. Milano: Edizioni Unicopi, 1986: 175210.
  • 40
    Inoue M, Tajima K, Matsuura A, et al. Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Lett 2000; 161: 10512.
  • 41
    McColl KE, El-Omar E, Gillen D, Banerjee S. The role of Helicobacter pylori in the pathophysiology of duodenal ulcer disease and gastric cancer. Semin Gastrointest Dis 1997; 8: 14255.
  • 42
    Leach SA, Thompson M, Hill M. Bacterially catalysed N-nitrosation reactions and their relative importance in the human stomach. Carcinogenesis 1987; 8: 190712.
  • 43
    Lipkin M, Correa P, Mikol YB, et al. Proliferative and antigenic modifications in human epithelial cells in chronic atrophic gastritis. J Natl Cancer Inst 1985; 75: 6139.
  • 44
    Konturek PC, Rembiasz K, Konturek SJ, et al. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci 2003; 48: 3646.
  • 45
    Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981; 9: 120.
  • 46
    Patchett SE, Alstead EM, Butruk L, Przytulski K, Farthing MJ. Ornithine decarboxylase as a marker for premalignancy in the stomach. Gut 1995; 37: 136.
  • 47
    Russo F, Linsalata M, Giorgio I, Caruso ML, Armentano R, Di Leo A. Polyamine levels and ODC activity in intestinal-type and diffuse-type gastric carcinoma. Dig Dis Sci 1997; 42: 5769.
  • 48
    Testino G, Valentini M, Cornaggia M, Testino R. Chronic atrophic gastritis and gastric cancer. Dig Liver Dis 2000; 32: 544.
  • 49
    Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16: 120916.
  • 50
    Shimoyama T, Fukuda S, Tanaka M, Nakaji S, Munakata A. Evaluation of the applicability of the gastric carcinoma risk index for intestinal type cancer in Japanese patients infected with Helicobacter pylori. Virchows Arch 2000; 436: 5857.
  • 51
    Jass JR, Filipe MI. Sulphomucins and precancerous lesions of the human stomach. Histopathology 1980; 4: 2719.
  • 52
    Ho SB, Shekels LL, Toribara NW, et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 1995; 55: 268190.
  • 53
    Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999; 59: 10037.
  • 54
    Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57: 3249.
  • 55
    Matsukura N, Suzuki K, Kawachi T, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980; 65: 23140.
  • 56
    You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 1999; 83: 6159.
  • 57
    Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 13843.
  • 58
    Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95: 14318.
    Direct Link:
  • 59
    Gong C, Mera R, Bravo JC, et al. KRAS mutations predict progression of preneoplastic gastric lesions. Cancer Epidemiol Biomarkers Prev 1999; 8: 16771.
  • 60
    Chung IK, Hwang KY, Kim IH, et al. Helicobacter pylori and telomerase activity in intestinal metaplasia of the stomach. Korean J Intern Med 2002; 17: 22733.
  • 61
    Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000; 156: 53743.
  • 62
    Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001; 61: 284751.
  • 63
    Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol 1994; 144: 5117.
  • 64
    Yu J, Leung WK, Ng EK, et al. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther 2001; 15: 150511.
  • 65
    Silberg DG, Furth EE, Taylor JK, Schuck T, Chiou T, Traber PG. CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium. Gastroenterology 1997; 113: 47886.
  • 66
    Satoh K, Mutoh H, Eda A, et al. Aberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: effect of eradication of Helicobacter pylori. Helicobacter 2002; 7: 1928.
  • 67
    Hamamoto T, Yokozaki H, Semba S, et al. Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J Clin Pathol 1997; 50: 8416.
  • 68
    Ottini L, Palli D, Falchetti M, et al. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res 1997; 57: 45239.
  • 69
    Nardone G, Staibano S, Rocco A, et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 1999; 44: 78999.
  • 70
    Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 1994; 35: 1697700.
  • 71
    Ochiai A, Yamauchi Y, Hirohashi S. p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 1996; 69: 2833.
  • 72
    Wu MS, Shun CT, Lee WC, et al. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia. Br J Cancer 1998; 78: 1258.
  • 73
    Fenoglio-Preiser C, Carneiro F, Correa P, et al. Gastric carcinoma. In: Hamilton, SR, Aaltonen, LA, eds. Pathology and Genetics, Tumors of the Digestive System. Lyon: IARC press, 2000: 3952.
  • 74
    Genta RM, Rugge M. Gastric precancerous lesions: heading for an international consensus. Gut 1999; 45: 158.
  • 75
    Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113: S5660.
  • 76
    Macartney JC, Camplejohn RS. DNA flow cytometry of histological material from dysplastic lesions of human gastric mucosa. J Pathol 1986; 150: 1138.
  • 77
    Abdel-Wahab M, Attallah AM, Elshal MF, et al. Correlation between endoscopy, histopathology, and DNA flow cytometry in patients with gastric dyspepsia. Hepatogastroenterology 1996; 43: 131320.
  • 78
    Li J, Zhao A, Lu Y, Wang Y. Expression of p185erbB2 and p21ras in carcinoma, dysplasia, and intestinal metaplasia of the stomach: an immunohistochemical and in situ hybridization study. Semin Surg Oncol 1994; 10: 959.
  • 79
    Sanz-Ortega J, Sanz-Esponera J, Caldes T, Gomez de la Concha E, Sobel ME, Merino MJ. LOH at the APC/MCC gene (5Q21) in gastric cancer and preneoplastic lesions. Prognostic implications. Pathol Res Pract 1996; 192: 120610.
  • 80
    Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 714.
  • 81
    Tepes B, Kavcic B, Zaletel LK, et al. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 188: 249.
  • 82
    Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 144956.
  • 83
    Genta RM, Franceschi F. Gastric markers of pre-malignancy are not reversible. In: Hunt, RH, Tytgut, GNJ, eds. Helicobacter pylori– Basic Mechanisms to Clinical Cure 2000. Hamilton: Kluwer Academic Publisher, 2000: 52434.
  • 84
    Franceschi F, Genta RM, Sepulveda AR. Gastric mucosa: long-term outcome after cure of Helicobacter pylori infection. J Gastroenterol 2002; 37: 1723.
  • 85
    Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 192332.
  • 86
    van Grieken NC, Meijer GA, Weiss MM, et al. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol 2001; 96: 28826.
    Direct Link:
  • 87
    Kokkola A, Sipponen P, Rautelin H, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002; 16: 51520.
  • 88
    Sugiyama T, Sakaki N, Kozawa H, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002; 16: 18790.
  • 89
    Nada R, Bhasin DK, Joshi K, et al. Effect of eradication of Helicobacter pylori on gastric antrum histology. Trop Gastroenterol 2002; 23: 204.
  • 90
    Annibale B, Di Giulio E, Caruana P, et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther 2002; 16: 172331.
  • 91
    Yamada T, Miwa H, Fujino T, Hirai S, Yokoyama T, Sato N. Improvement of gastric atrophy after Helicobacter pylori eradication therapy. J Clin Gastroenterol 2003; 36: 40510.
  • 92
    Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 1220.
  • 93
    Satoh K. Does eradication of Helicobacter pylori reverse atrophic gastritis or intestinal metaplasia? Data from Japan. Gastroenterol Clin North Am 2000; 29: 82935.
  • 94
    Zullo A, Rinaldi V, Hassan C, et al. Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study. Aliment Pharmacol Ther 2000; 14: 13039.
  • 95
    Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 18818.
  • 96
    Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 2002; 102: 3944.
  • 97
    Rugge M, Cassaro M, Pennelli G, Leandro G, Di Mario F, Farinati F. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 2003; 52: 13878.
  • 98
    Staibano S, Rocco A, Mezza E, De Rosa G, Budillon G, Nardone G. Diagnosis of chronic atrophic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. J Pathol 2002; 198: 4754.
  • 99
    Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 124959.
  • 100
    El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30: 727.
  • 101
    Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet 1997; 349: 17259.
  • 102
    Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 2001; 49: 24.
  • 103
    Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 2002; 3: 18794.
  • 104
    Ishikawa N, Wakelin D, Mahida YR. Role of T helper 2 cells in intestinal goblet cell hyperplasia in mice infected with Trichinella spiralis. Gastroenterology 1997; 113: 5429.
  • 105
    Tahara E. Molecular biology of gastric cancer. World J Surg 1995; 19: 4848.
  • 106
    Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 2515.
  • 107
    Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52: 11116.
  • 108
    Glober GA, Cantrell EG, Doll R, Peto R. Interaction between ABO and rhesus blood groups, the site of origin of gastric cancers, and the age and sex of the patient. Gut 1971; 12: 5703.
  • 109
    Go MF. Review article: Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 315.
  • 110
    Asaka M, Kudo M, Kato M, Sugiyama T, Takeda H. Review article: Long-term Helicobacter pylori infection – from gastritis to gastric cancer. Aliment Pharmacol Ther 1998; 12: 915.
  • 111
    Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem 1996; 377: 67584.
  • 112
    Heyden JD, Martin IG, Cawkwell L. The role of microsatellite instability in gastric carcinoma. Gut 1998; 42: 3003.
  • 113
    Eshleman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995; 7: 839.
  • 114
    Gayter SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998; 58: 40869.
  • 115
    Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 18794.
  • 116
    Kuniyasu H, Yasui W, Yokozaki H, Tahara E. Helicobacter pylori infection and carcinogenesis of the stomach. Langenbecks Arch Surg 2000; 385: 6974.
  • 117
    Tahara E. Molecular mechanism of human stomach carcinogenesis implicated in Helicobacter pylori infection. Exp Toxicol Pathol 1998; 50: 3758.
  • 118
    Sugimura T, Ushijima T. Genetic and epigenetic alterations in carcinogenesis. Mutat Res 2000; 462: 23546.
  • 119
    Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002; 3: 75563.
  • 120
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 6439.
  • 121
    Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003; 83: 63541.
  • 122
    Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylation-dependent gene silencing induced by interleukin 1ß via nitric oxide production. J Exp Med 2000; 190: 15951604.
  • 123
    Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol 2004; 19: 2218.